"Weight-loss injection" is the everyday term for a small group of prescription medicines known as GLP-1 receptor agonists. In the UK, the two best-known injectable options used in medical weight management are Wegovy (semaglutide) and Mounjaro (tirzepatide). They sound new — and the public conversation around them is recent — but the underlying class of medicine has been used in type 2 diabetes for over fifteen years, with a well-mapped safety profile.

What GLP-1 receptor agonists are and how they act

GLP-1 stands for "glucagon-like peptide-1". It is a hormone the gut naturally releases after a meal. Its job is part of the body's feedback loop after eating: it signals fullness to the brain, slows the rate at which the stomach empties into the small intestine, and prompts the pancreas to release insulin in response to food. In someone living with overweight or obesity, that system often runs less strongly than it could — hunger signals come back sooner, satiety signals are weaker, and the cycle is harder to break with willpower alone.

A GLP-1 receptor agonist is a medicine designed to mimic the natural hormone and bind to the same receptors. Semaglutide (the active ingredient in Wegovy and several diabetes products such as Ozempic) is a GLP-1 analogue. Tirzepatide (the active ingredient in Mounjaro) is a dual agonist — it acts on both the GLP-1 receptor and the GIP receptor, a second gut hormone receptor involved in similar pathways. Both are given as once-weekly injections at gradually escalating doses.

Other licensed options exist alongside the injectables. Older treatments such as orlistat work by a completely different mechanism (reducing fat absorption in the gut), and oral GLP-1 options such as Rybelsus exist for patients who prefer tablets. Older daily injectables such as Saxenda (liraglutide) are still used in some cases. Choice depends on clinical suitability, not preference alone.

Appetite signalling and gastric emptying

The day-to-day experience patients report on a GLP-1 injection comes from two main mechanisms working together.

First, the medicine strengthens central appetite signals. Receptors in the brain — particularly in regions involved in hunger, reward and food-related decision-making — are activated, with the result that hunger is reduced, satiety arrives sooner, and the constant background "food noise" that many patients describe quietens. The same meal that previously left someone wanting more often feels enough.

Second, the medicine slows gastric emptying — the rate at which the stomach hands food on to the small intestine. The result is a more prolonged sense of fullness after eating. The same biological effect is also responsible for the most common side effects of treatment, especially in the early weeks: nausea, reduced appetite, mild reflux, and (less often) loose stools or constipation. For more on that, see our piece on how long Mounjaro side effects last.

A third mechanism matters in patients with type 2 diabetes: GLP-1 medicines improve insulin release in response to meals and reduce the post-meal rise in glucagon. That helps blood-sugar control, which is why these medicines were licensed for diabetes first.

None of these mechanisms alter the body's resting metabolism in a magical way. The weight loss patients see is the cumulative result of eating less consistently because hunger signals are quieter — supported by other habit changes that become easier when food is no longer dominating attention.

What an injection treatment course looks like in the UK

Weight-loss injections come as pre-filled pens designed for self-injection at home, once a week. The needle is short and fine, the technique is straightforward, and your clinician or pharmacist walks you through it at the start. Injection sites rotate week to week between the abdomen, thigh and upper arm.

Treatment starts at a low "starter" dose, held for several weeks. The starter dose is not really about weight loss — its job is to let the body adapt to the medicine before reaching the level at which most patients begin to see meaningful weight change. Dose increases then happen on a schedule, with at least four weeks at each step, and only if the previous dose has been tolerated. This pattern is the same logic for every UK-licensed weight-loss injectable: slow titration, regular review, joint decisions.

A typical course looks something like this:

  • Initial consultation: a UK-registered prescriber reviews your medical history, current medications, BMI and weight-related conditions, and discusses suitability and expectations.
  • Starter phase: the first four weeks are about tolerability rather than results.
  • Titration phase: dose increases every four weeks where appropriate, with regular clinical review.
  • Maintenance phase: once you reach a dose that gives steady progress with tolerable side effects, you stay there. The right maintenance dose is the one that works for you; it is not always the highest licensed dose.
  • Ongoing review: reviews continue while you are on treatment, typically monthly during titration and less often once stable.

For more on the dose-step logic, see our piece on when to increase your Mounjaro dose for weight loss.

Who is eligible per UK clinical thresholds

UK eligibility for weight-loss injections is not a marketing decision — it is set by NICE and applied by your prescribing clinician, with the BNF setting out the cautions and contraindications. Eligibility is built around two main pieces of information: your BMI and whether you have any weight-related comorbidities.

In broad terms, NICE guidance recognises a role for pharmacological weight-management treatment in adults with:

  • A BMI of 30 kg/m² or above, or
  • A BMI of 27 kg/m² or above with at least one weight-related condition — type 2 diabetes, prediabetes, high blood pressure, cardiovascular disease, obstructive sleep apnoea, or certain others.

BMI thresholds may be adjusted for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, where weight-related health risk increases at lower BMI values. The clinical picture as a whole — not the number alone — guides the prescribing decision.

The shared assumption across UK guidance is that pharmacological treatment is one part of a programme, not the whole programme. Diet, activity and behavioural support sit alongside the medicine. Treatment is not appropriate in pregnancy or breastfeeding, and there are specific contraindications relating to gastrointestinal disease and certain endocrine conditions. A clinician's job at the initial consultation is to walk through this picture properly.

What questions to ask a clinician

An honest conversation up front sets the right expectations. Useful questions to bring to an initial consultation include:

  • Am I eligible based on my BMI, comorbidities and full medical history?
  • What is a realistic weight-loss trajectory for someone with my picture? What do the trial averages look like, and where might I sit on that curve?
  • How will dose changes be handled, and what will the reviews look like during titration?
  • What side effects should I expect, and how long do they typically last?
  • What happens if I want to stop — gradually or suddenly — and what is the usual pattern after stopping?
  • Are there interactions with my other medications that I should know about?
  • What lifestyle changes will most support the treatment in my case?
  • What does the pharmacy supply process look like, and how will the medicine reach me?

It is also fair to ask about cost, length of expected treatment, and what happens at maintenance. There are no silly questions at the start; an upfront clinician will welcome them.

What weight-loss injections are not

A short word on what these medicines are not. They are not appetite-suppressant stimulants. They are not a substitute for the slow, gradual habit work that long-term weight management depends on. They do not produce the same outcome in every patient, and trial averages are not promises. And they are not over-the-counter products — in the UK, they are prescription-only and dispensed by a GPhC-registered pharmacy under a clinician's prescription, with regulation from the MHRA.

Used the way they were designed — as a clinical tool inside a structured programme — they are one of the most significant advances in obesity treatment in a generation. Used outside that framework, the picture is different. The job of a Farmeci consultation is to make sure the framework is the one in place.

Working with your Farmeci clinician

In a Farmeci programme, your initial consultation is with a UK-registered clinician. They will review your medical history, weight, BMI, current medications and weight-related conditions; they will discuss expectations and answer questions honestly; and, if treatment is appropriate, they will agree a starting plan with you. From there, reviews continue throughout treatment — monthly during titration, less often once stable. Continuation of treatment is reviewed periodically by a clinician, not assumed indefinitely. For an honest take on what to do when response is slower than hoped, see our piece on why you may not be losing weight on Mounjaro.